Drugs / Epitinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03231501 | Jan 2018 → Jun 2020 | glioblastoma | Hutchison Medipharma Limited | Unknown | No outcome recorded |
| Phase 1 | NCT02590952 | Oct 2011 → Apr 2019 | cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-03-06 | Hutchison Medipharma Limited | Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China hutch-med.com ↗ |
| 2016-11-23 | Hutchison Medipharma Limited | Chi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”) hutch-med.com ↗ |
| 2014-04-04 | Hutchison Medipharma Limited | Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting hutch-med.com ↗ |
| 2011-11-04 | Hutchison Medipharma Limited | Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib hutch-med.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02590952 ↗ |
| Known as | HMPL-813 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314411 ↗ |
| Action | Inhibit | “Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor.” NCT02590952 ↗ |
| Modality | Small molecule | “epitinib, which is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)” NCT03231501 ↗ |
| Route | Oral | “Route: oral (daily)” NCT02590952 ↗ |
| Target | EGFR | “Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor.” NCT02590952 ↗ |